Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

PROSHARES TRUST (ZBIO) EBIT: 2023-2024

Historic EBIT for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to -$163.9 million.

  • Zenas BioPharma's EBIT fell 28.29% to -$52.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$200.7 million, marking a year-over-year decrease of 50.85%. This contributed to the annual value of -$163.9 million for FY2024, which is 341.19% down from last year.
  • Per Zenas BioPharma's latest filing, its EBIT stood at -$163.9 million for FY2024, which was down 341.19% from -$37.1 million recorded in FY2023.
  • In the past 5 years, Zenas BioPharma's EBIT ranged from a high of -$37.1 million in FY2023 and a low of -$163.9 million during FY2024.
  • For the 2-year period, Zenas BioPharma's EBIT averaged around -$100.5 million, with its median value being -$100.5 million (2023).
  • Data for Zenas BioPharma's EBIT shows a maximum YoY crashed of 341.19% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Zenas BioPharma's EBIT stood at -$37.1 million in 2023, then plummeted by 341.19% to -$163.9 million in 2024.